T0	Participants 157 193	advanced colorectal cancer patients.
T1	Participants 615 695	advanced colorectal cancer (ACC) patients treated in the phase III CAIRO2 study.
T2	Participants 718 780	Seven hundred and fifty five previously untreated ACC patients
T3	Participants 1116 1168	Seven hundred and thirty two patients were evaluable